Publications by authors named "Samuel Grigg"
Article Synopsis
- The study focused on patients with aggressive B-cell non-Hodgkin lymphoma who experienced relapse after treatment with glofitamab, finding a poor prognosis and low response rates to further therapies.
- On average, patients had a median overall survival of just 4.1 months after their condition progressed, indicating a significant challenge in treatment outcomes.
- Notably, 59% of patients showed loss of the CD20 marker at relapse, suggesting a need for further research on CD20 loss mechanisms and exploration of new treatments that do not target CD20.
Purpose: To assess the impact of a pathway allowing nurse initiation of first dose intravenous (IV) antibiotics on time to antibiotic administration (TTA) in adult inpatients with febrile neutropenia (FN).
Methods: This study evaluated the impact on TTA of a clinical pathway (November 2017 to April 2018) allowing nurse initiation of pre-prescribed antibiotics in adult haematology patients with FN, compared with a prior cohort (November 2016 to April 2017) in which antibiotics were only prescribed and administered after medical review. The primary endpoint for comparison was TTA, calculated as the time between the first recorded fever and IV antibiotic administration.